At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
argatrobandrug
Likely dose
argatroban 1mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study To Determine The Safety Of Argatroban Injection In Combination With Tissue Plasmingen Activator (TPA) In Patients With Acute Ischemic Stroke
The University of Texas Health Science Center, Houston·interventional·Posted Dec 22, 2005·Updated Nov 10, 2014
In Brief
A Phase 2 clinical trial evaluating argatroban for Ischemic Stroke. Completed, enrolled 65 participants across 6 sites.
Detailed Summary
Is the combination of low doses of argatroban in combination with rt-PA safe, and does it increase recanalization in patients with acute ischemic stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2003
First PostedDec 2005
Primary CompletionAug 2010
TodayJul 2026
First PostedDec 22, 2005
Enrollment StartFeb 1, 2003
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 20.5 years ago
Interventions
argatrobandrug
Argatroban IV Infusion at 1mcg/kg/min for 48 hours.